Pay in 4 interest-free payments of $5.38 Learn more
Ships within 48 hours · Estimated delivery Aug 5 - Aug 10
The published research literature has investigated: GHRH receptor activation in pituitary somatotroph cells Pulsatile release of endogenous growth hormone Subsequent IGF-1 elevation through downstream GH signaling Maintained natural feedback regulation through somatostatin and IGF-1 DPP-4-resistant pharmacokinetics from the trans-3-hexenoic acid modification The two compounds produce fundamentally different research effects: AOD-9604 produces lipolytic activity without affecting IGF-1 or broader GH-mediated signaling Tesamorelin produces full GH axis activation including IGF-1 elevation and broader GH-mediated effects Pharmacokinetic Comparison The compounds have different pharmacokinetic profiles: AOD-9604
However, the list includes an S0 category for pharmacological substances that are not addressed elsewhere and have no current approval by a governmental regulatory health authority for human therapeutic use
NNMT normally burns through NAD+ precursors as a kind of metabolic "bleed." Block the bleed, and MOTS-C's expanded mitochondrial activity has more substrate to work with
The CAS registry number for AOD9604 is 221231-10-3
Is Semaglutide (Ozempic) Right for You
